Vicebio
UK - LondonBiotechnology
Focus: Molecular Clamp technology platform for vaccines against life-threatening respiratory viral infections
Vicebio is a life sciences company focused on Molecular Clamp technology platform for vaccines against life-threatening respiratory viral infections.
Profile data last refreshed Yesterday
Open Jobs
0
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
trivalent
Lower Respiratory Tract DiseaseClinical Trials (1)
NCT07295028Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults
Phase 1Help build intelligence for Vicebio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.